Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma

Gynecol Oncol. 2005 Apr;97(1):136-41. doi: 10.1016/j.ygyno.2004.12.002.

Abstract

Background: The aim of this study was to determine the rates and topography of pelvic and para-aortic nodal involvement in patients with stage III or IV primary peritoneal serous papillary carcinoma (PSPC).

Methods: Retrospective review of 19 women who underwent a systematic bilateral pelvic and para-aortic lymphadenectomy.

Results: The overall frequency of lymph node involvement was 63% (12/19). Eighteen patients underwent complete resection of peritoneal disease. Only 4 patients underwent this procedure as part of their initial surgery (before chemotherapy). The frequency of pelvic and para-aortic metastases was 58% (11/19) and 58% (11/19), respectively. When para-aortic nodes were involved, the left para-aortic chain above the level of the inferior mesenteric artery was the site most frequently involved (72%). The event-free survival of the 18 patients without macroscopic disease at the end of debulking surgery was significantly correlated with the nodal status. None of the patients with positive nodes developed recurrent disease in abdominal nodes.

Conclusions: The rate of nodal involvement in patients with PSPC is high. The topography of nodal spread is similar to that of ovarian cancer. Lymphadenectomy has a prognostic value.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Aorta
  • Carcinoma, Papillary / drug therapy
  • Carcinoma, Papillary / pathology*
  • Carcinoma, Papillary / surgery
  • Combined Modality Therapy
  • Cystadenocarcinoma, Serous / drug therapy
  • Cystadenocarcinoma, Serous / pathology*
  • Cystadenocarcinoma, Serous / surgery
  • Female
  • Humans
  • Lymph Node Excision
  • Lymph Nodes / pathology*
  • Lymph Nodes / surgery
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Staging
  • Organoplatinum Compounds / administration & dosage
  • Paclitaxel / administration & dosage
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / pathology*
  • Peritoneal Neoplasms / surgery
  • Retrospective Studies

Substances

  • Organoplatinum Compounds
  • Paclitaxel